Ztalmy Unia Europejska - polski - EMA (European Medicines Agency)

ztalmy

marinus pharmaceuticals emerald limited - ganaxolone - epileptic syndromes; spasms, infantile - inne przeciwpadaczkowe narzędzia - ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 to 17 years of age. ztalmy may be continued in patients 18 years of age and older.